Pharmacokinetics of metformin after intravenous and oral administration to man
- PMID: 499320
- DOI: 10.1007/BF00562061
Pharmacokinetics of metformin after intravenous and oral administration to man
Abstract
The kinetics of 14C-metformin have been studied in five healthy subjects after oral and intravenous administration. The intravenous dose was distributed to a small central compartment of 9.9 +/- 1.61 (X +/- SE), from which its elimination could be described using three-compartment open model. The elimination half-life from plasma was 1.7 +/- 0.1 h. Urinary excretion data revealed a quantitatively minor terminal elimination phase with a half-life of 8.9 +/- 0.7 h. After the intravenous dose, metformin was completely excreted unchanged in urine with a renal clearance of 454 +/- 47 ml/min. Metformin was not bound to plasma proteins. The concentration of metformin in saliva was considerably lower than in plasma and declined more slowly. The bioavailability of metformin tablets averaged 50--60%. The rate of absorption was slower than that of elimination, which resulted in a plasma concentration profile of "flip-flop" type for oral metformin.
Similar articles
-
Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products.Int J Clin Pharmacol Ther Toxicol. 1986 Apr;24(4):213-20. Int J Clin Pharmacol Ther Toxicol. 1986. PMID: 3710634 Clinical Trial.
-
The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects.Eur J Clin Pharmacol. 1980 May;17(5):385-91. doi: 10.1007/BF00558453. Eur J Clin Pharmacol. 1980. PMID: 7418717
-
The pharmacokinetics of saccharin in man.Xenobiotica. 1981 Aug;11(8):531-40. doi: 10.3109/00498258109045864. Xenobiotica. 1981. PMID: 7303723
-
Disposition of metformin (N,N-dimethylbiguanide) in man.Clin Pharmacol Ther. 1978 Dec;24(6):683-93. doi: 10.1002/cpt1978246683. Clin Pharmacol Ther. 1978. PMID: 710026
-
Clinical pharmacokinetics of metformin.Clin Pharmacokinet. 1996 May;30(5):359-71. doi: 10.2165/00003088-199630050-00003. Clin Pharmacokinet. 1996. PMID: 8743335 Review.
Cited by
-
Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy.Pharmgenomics Pers Med. 2011;4:11-33. doi: 10.2147/PGPM.S18861. Epub 2011 Apr 1. Pharmgenomics Pers Med. 2011. PMID: 23226051 Free PMC article.
-
The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.Clin Pharmacol Ther. 2013 Feb;93(2):186-94. doi: 10.1038/clpt.2012.210. Epub 2012 Oct 17. Clin Pharmacol Ther. 2013. PMID: 23267855 Free PMC article.
-
Effect of metformin on glucose metabolism in the splanchnic bed.Br J Pharmacol. 1992 Apr;105(4):1009-13. doi: 10.1111/j.1476-5381.1992.tb09093.x. Br J Pharmacol. 1992. PMID: 1504710 Free PMC article.
-
Metformin therapy in pediatric type 2 diabetes mellitus and its comorbidities: A review.Front Endocrinol (Lausanne). 2023 Feb 6;13:1072879. doi: 10.3389/fendo.2022.1072879. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36814831 Free PMC article. Review.
-
Pharmacokinetic-Pharmacodynamic Modeling of Metformin for the Treatment of Type II Diabetes Mellitus.Open Biomed Eng J. 2011;5:1-7. doi: 10.2174/1874120701105010001. Epub 2011 Jan 19. Open Biomed Eng J. 2011. PMID: 21625374 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources